

Supplementary material to

## Potential effect of nanoformulated iota carrageenan in A $\beta$ 1-42 disaggregation: an *in vitro*, *in vivo* and *in silico* study


Saranya Udayakumar<sup>1</sup>, Sanjay Kisan Metkar<sup>2</sup>, Koyeli Girigoswami<sup>3</sup> and Agnishwar Girigoswami<sup>1</sup>

<sup>1</sup>Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, TN-603103, India

<sup>2</sup>Department of Pharmacology, Physiology & Neuroscience, Rutgers, The State University of New Jersey, 205 South Orange Avenue, Newark, NJ 07103, USA

<sup>3</sup>Medical Bionanotechnology Laboratory, Department of Obstetrics and Gynaecology, Centre for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, 602105, India

ADMET & DMPK 14 (2026) 3122; <https://doi.org/10.5599/admet.3122>



**Figure S1.** Morphological observation of PC12 cells after treatment with sample groups: (A) control; (B) CG high dose (20  $\mu\text{g mL}^{-1}$ ) (C) nCG high dose (20  $\mu\text{g mL}^{-1}$ ); (D) A $\beta$  1-42 (20  $\mu\text{g mL}^{-1}$ ); (E) A $\beta$  1-42 + CG (5  $\mu\text{g mL}^{-1}$ ); (F) A $\beta$  1-42 + nCG (5  $\mu\text{g mL}^{-1}$ )